Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sheng Xuexiaoban Capsules in relapsed/refractory primary immune thrombocytopenia
ChiCTR2300073565Phase 4Not yet recruiting
- Sponsor
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Start
- Jul 2023
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Sheng Xuexiaoban Capsules in immune thrombocytopenia (ITP), sponsored by First Teaching Hospital of Tianjin University of Traditional Chinese Medicine. Primary endpoints: Total effective rate, Platelet count and 5 more. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
Sheng Xuexiaoban Capsules
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2300073565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073565.